Weak Patents Are a Weak Deterrent: Patent Portfolios, the Orange Book Listing Standard, and Generic Entry in Pharmaceuticals
This chapter is a preliminary draft unless otherwise noted. It may not have been subjected to the formal review process of the NBER. This page will be updated as the chapter is revised.
Chapter in forthcoming NBER book Standards, Patents and Innovations, Timothy Simcoe, Ajay K. Agrawal, and Stuart Graham, organizers
This chapter is not currently available on-line.